about
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review.Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry.Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline.Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention.Nutritional Interventions and Cognitive-related Outcomes in Patients with Late-life Cognitive Disorders: A Systematic ReviewSocial Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE StudyNutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic ReviewPharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorderThe Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear.Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia StudyPromising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugsBiopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on agingCorrigendum to "Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review" Neurosci. Biobehav. Rev. 95 (2018) 480-498Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese SubjectsSensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later lifeGeneralizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
P50
Q38966308-78F6AEC0-1131-41C6-941E-2EA5C457CFA6Q39428946-C217E567-A821-44E5-96B9-CD7313F2F8B1Q40058836-B4D5D0FC-4505-4090-954E-05979581C6C1Q47703267-0D66DD5D-F787-45CD-BDDA-319BC2B185C6Q51760882-61E26A26-5397-4631-BE5A-4C14CFB3A4B0Q58617641-7334C84C-AEB6-481C-8D1C-DB2D7928171BQ60050493-17FE96B5-AE41-4736-A9E8-0AFEA1FCD38DQ64045182-C836E217-BA87-4B99-BBB9-0CADDF597674Q64045682-A1F07C9C-7C7D-4D0A-9A2D-5D88278CE943Q64993120-D67E2FC5-A39F-418D-96F2-4F5449724597Q89657800-A809FE2D-B938-45E6-9DA2-B6C7483E353BQ90011177-36D6C542-0B81-42BC-B01D-97B1480B2383Q91663460-CA55DBED-E3BF-4B21-8BE0-E79CF7092B47Q91775326-F68FBF3B-D7D4-4D08-8D14-0DF9778741C9Q91811667-90C8879D-7A52-473B-9D81-4D9D42FE1DDEQ92890568-66198C2E-3169-4BED-8E93-8ED9329AE832Q96352950-A3AB3299-252D-4158-9B02-76454A78461E
P50
description
researcher
@en
wetenschapper
@nl
name
Rodolfo Sardone
@en
Rodolfo Sardone
@nl
type
label
Rodolfo Sardone
@en
Rodolfo Sardone
@nl
prefLabel
Rodolfo Sardone
@en
Rodolfo Sardone
@nl
P31
P496
0000-0003-1383-1850